• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 6-K filed by Bon Natural Life Limited

    4/2/25 9:57:55 PM ET
    $BON
    Medicinal Chemicals and Botanical Products
    Health Care
    Get the next $BON alert in real time by email
    6-K 1 form6-k.htm

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

    FORM 6-K

     

    REPORT OF FOREIGN PRIVATE ISSUER

    PURSUANT TO RULE 13a-16 OR 15d-16 OF THE

    SECURITIES EXCHANGE ACT OF 1934

     

    For the month of April 2025

     

    Commission File Number 001-40517

     

    BON NATURAL LIFE LIMITED

    (Translation of registrant’s name into English)

     

    Room 601, Block C, Gazelle Valley, No.69, Jinye Road

    High-Tech Zone, Xi’an, Shaanxi, China

    People’s Republic of China

    (Address of principal executive offices)

     

    Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F: Form 20-F ☒ Form 40-F ☐

     

    Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐

     

    Note: Regulation S-T Rule 101(b)(1) only permits the submission in paper of a Form 6-K if submitted solely to provide an attached annual report to security holders.

     

    Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐

     

    Note: Regulation S-T Rule 101(b)(7) only permits the submission in paper of a Form 6-K if submitted to furnish a report or other document that the registrant foreign private issuer must furnish and make public under the laws of the jurisdiction in which the registrant is incorporated, domiciled or legally organized (the registrant’s “home country”), or under the rules of the home country exchange on which the registrant’s securities are traded, as long as the report or other document is not a press release, is not required to be and has not been distributed to the registrant’s security holders, and, if discussing a material event, has already been the subject of a Form 6-K submission or other Commission filing on EDGAR.

     

     

     

     

     

     

    Pending Share Consolidation (Reverse Split) and Increased in Authorized Shares

     

    Subject to the further approval of the majority of our shareholders, our Board of Directors has approved a reverse split (a “share consolidation” under Cayman Islands law) at a ratio of one (1) Class A ordinary share for every twenty-five (25) Class A ordinary shares issued and outstanding (the “Reverse Split”). Upon completion of the Reverse Split, every twenty-five (25) issued and outstanding Class A ordinary shares will be consolidated into one (1) Class A ordinary share. Any fractional shares resulting from the Reverse Split will be rounded to the next whole share. Immediately following the Reverse Split, and also subject to the further approval of a majority of our shareholders, our Board of Directors has approved an increase in our authorized share capital such that we will have: (i) 1,000,000,000 authorized Class A ordinary shares, par value $0.025 per share; (ii) 50,000,000 Class B ordinary shares, pare value $0.001 per share; and (iii) 50,000,000 preference shares, par value $0.001 per share. The preference shares may be issued in the future, upon approval of the Board of Directors, in one or more classes or series, with rights and limitations of each class or series with regard to voting, dividends, convertability, and other powers, preferences and relative, participating, optional and other special rights, and any qualifications, limitations and restrictions, as may be designated by the Board for each designated class.

     

    In addition to the Reverse Split and increase in authorized shares, and subject to the further approval of a majority of our shareholders, our Board of Directors has approved an amendment to the conversion rate (as defined in the Articles) of the Class B ordinary shares. Currently, Class B ordinary shares are convertible to Class A ordinary shares on a one-to-one (1:1) basis. Under the amendment, Class B ordinary shares will be convertible to Class A ordinary shares at a rate of twenty-five (25) Class B ordinary shares to one (1) Class A ordinary share (the “Variation of Class Rights”). The proposed Reverse Split, Variation of Class Rights, and increase in authorized shares will be accomplished by way of an amendment to our charter documents, to be reflected in the proposed Fourth Amended and Restated Memorandum of Association (the “Fourth Amended MA”) and Fourth Amended and Restated Articles of Association (the “Fourth Amended AA”) filed herewith as Exhibits 3.1 and 3.2, respectively.

     

    Special Shareholder Meeting

     

    For the purposes of seeking shareholder approval of the Reverse Split, the increase in authorized shares, the Variation of Class Rights, the Fourth Amended MA, and the Fourth Amended AA, our Board of Directors has scheduled an extraordinary general meeting of shareholders to be held under Cayman Islands law. The meeting will be held on April 15, 2025 at 10:00 a.m. (Beijing time) at Room 601, Block C, Gazelle Valley, No.69, Jinye Road, High-Tech Zone, Xi’an, Shaanxi, China. All shareholders of record as of March 26, 2025 are entitled to vote at the meeting in person or by proxy. A copy of the Notice of Extraordinary General Meeting is furnished herewith as Exhibit 99.1

     

    Exhibits

     

    The following exhibits are included in this Form 6-K:

     

    Exhibit No.   Description of Exhibit

    3.1

     

    Fourth Amended and Restated Memorandum of Association (proposed)

    3.2   Fourth Amended and Restated Articles of Association (proposed)
    99.1   Notice of Extraordinary General Meeting

     

     

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

     

    Date: April 2, 2025 Bon Natural Life Limited
         
      By: /s/ Yongwei Hu
        Yongwei Hu
        Chairman and Chief Executive Officer

     

     

     

    Get the next $BON alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $BON

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $BON
    SEC Filings

    See more
    • SEC Form 6-K filed by Bon Natural Life Limited

      6-K - Bon Natural Life Ltd (0001816815) (Filer)

      5/22/25 3:16:58 PM ET
      $BON
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form 6-K filed by Bon Natural Life Limited

      6-K - Bon Natural Life Ltd (0001816815) (Filer)

      5/16/25 9:05:19 AM ET
      $BON
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form 6-K filed by Bon Natural Life Limited

      6-K - Bon Natural Life Ltd (0001816815) (Filer)

      4/23/25 12:25:36 PM ET
      $BON
      Medicinal Chemicals and Botanical Products
      Health Care

    $BON
    Financials

    Live finance-specific insights

    See more
    • Bon Natural Life Limited Announces FY2022 Earnings Release Date and Webcast

      Earnings to be released before market opens on Friday, February 10, 2023 XIAN, China, Feb. 07, 2023 (GLOBE NEWSWIRE) -- Bon Natural Life Limited (NASDAQ:BON) ("BON" or the "Company"), one of the leading bio-ingredient solutions providers in the natural, health and personal care industries, will issue its FY2022 earnings release for the fiscal year ended September 30, 2021 before the market open on Friday, February 10, 2023. BON will also host an investor conference call and webcast on the same date, beginning at 9:00 a.m. EST. Management on the call will include CEO Mr. Richard (Yongwei) Hu, CFO Mr. Zhenchao Li, COO Ms. Yingchun Xue and CMO Wenjuan Chen. A replay of the call will also be

      2/7/23 8:30:00 AM ET
      $BON
      Medicinal Chemicals and Botanical Products
      Health Care
    • Bon Natural Life Limited Announces 2022 Half-Year Earnings Release Date and Webcast

      Earnings to be released before market opens on Monday, August 1, 2022XIAN, China, July 28, 2022 /PRNewswire/ -- Bon Natural Life Limited (NASDAQ:BON) ("BON" or the "Company"), one of the leading bio-ingredient solutions providers in the natural, health and personal care industries, will issue its half-year earnings release for the reporting period ended March 31, 2022 before the market open on Monday, August 1, 2022. BON will also host an investor conference call and webcast on the same date, beginning at 9:00 a.m. EST. Management on the call will include CEO Mr. Richard (Yongwei) Hu, CFO Mr. Zhenchao Li, COO Ms. Yingchun Xue and CMO Wenjuan Chen. A replay of the call will also be archived o

      7/28/22 4:30:00 PM ET
      $BON
      Medicinal Chemicals and Botanical Products
      Health Care
    • Bon Natural Life Limited Announces FY2021 Earnings Release Date and Webcast

      Earnings to be released before market opens on Monday, January 31, 2022 XI'AN, China, Jan. 28, 2022 /PRNewswire/ -- Bon Natural Life Limited (NASDAQ:BON) ("BON" or the "Company"), one of the leading bio-ingredient solutions providers in the natural, health and personal care industries, will issue its FY2021 earnings release for the fiscal year ended September 30, 2021 before the market open on Monday, January 31, 2022. In observation of Chinese New Year, BON will host an investor conference call and webcast on February 3 beginning at 9:00 a.m. EST. Management on the call will include CEO Mr. Richard (Yongwei) Hu, CFO Mr. Zhenchao Li, CMO Ms. Wenjuan Chen and COO Ms. Yingchun Xue. A replay

      1/28/22 9:00:00 AM ET
      $BON
      Medicinal Chemicals and Botanical Products
      Health Care

    $BON
    Leadership Updates

    Live Leadership Updates

    See more
    • Bon Natural Life Limited Appoints Wallace Lee as New Chief Financial Officer

      XIAN, China, April 25, 2023 (GLOBE NEWSWIRE) -- Bon Natural Life Limited (NASDAQ:BON) ("BON" or the "Company"), one of the leading bio-ingredient solutions providers in the natural, health and personal care industries, is pleased to announce the appointment of Mr. Wallace Lee as Chief Financial Officer (CFO), effective April 17, 2023. Mr. Lee succeeds Zhenchao Li, who stepped down from the role of CFO after a 4-year career with the Company, effective April 17, 2023. "We welcome Wallace Lee into BON's executive leadership team." Commented Richard Hu, "Wallace brings exceptional financial, strategic, and operational experience both from multiple industry sectors and experience as a public c

      4/25/23 8:30:00 AM ET
      $BON
      $SXTC
      $WSG
      Medicinal Chemicals and Botanical Products
      Health Care
      Biotechnology: Pharmaceutical Preparations
      Services-Misc. Amusement & Recreation
    • Bon Natural Life Limited Announces Change to Board Composition

      XIAN, China, June 30, 2022 /PRNewswire/ -- Bon Natural Life Limited (NASDAQ:BON) ("BON" or the "Company"), one of the leading bio-ingredient solutions providers in the natural, health and personal care industries, today announced the appointment of Jeffrey Guzy, as a new independent Director to its Board of Directors and as Chair of the Audit Committee, both effective June 28, 2022. Effective June 27, 2022, Mr. Christopher Constable resigned as a director of the Company for personal reasons and stepped down as a member and chairman of the audit committee of the Board. The resignation of Mr. Constable did not result from any dispute or disagreement with the Company or the Board on any matter

      6/30/22 4:30:00 PM ET
      $BON
      Medicinal Chemicals and Botanical Products
      Health Care

    $BON
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • BON Announces Launch of Tea Pigment Digestive Health Products and Cooperation Agreement Signed with Shanghai Risesun International Trade

      XI'AN, China, May 22, 2025 (GLOBE NEWSWIRE) -- Bon Natural Life Limited (NASDAQ:BON) ("BON" or the "Company"), a leading bio-ingredient solution provider in the natural, health and personal care industry, today announced a non-exclusive sales cooperation agreement with Shanghai Risesun International Trade Co., Ltd., a leading functional ingredient distributor in China. The term of the Agreement is 24 months with a total contract value of US$ 24 million. Pursuant to the agreement, Shanghai Risesun will market, distribute and sell BON's tea pigment series health products in China. Leveraging a robust biological profile that includes lipid modulation, glycemic control, antioxidant activity,

      5/22/25 9:00:00 AM ET
      $BON
      Medicinal Chemicals and Botanical Products
      Health Care
    • BON Announces The Launch Of Its Postbiotic Hypoglycemic Patented Ingredient Product Series And Its Cooperation Agreement

      XI'AN, China, May 16, 2025 (GLOBE NEWSWIRE) -- Bon Natural Life Limited (NASDAQ:BON) ("BON" or the "Company"), a leading bio-ingredient solution provider in the natural, health and personal care industry, announced an exclusive cooperation agreement with Beijing Huahai Keyuan (Tech) Co., Ltd., a leading functional ingredient distributor in China. The term of the agreement is 36 months with a total contract value of 32 million US dollars. Pursuant to the agreement, Beijing Huahai Keyuan will serve as the exclusive sales partner of BON's postbiotic hypoglycemic ingredients. BON aims to expand into the global blood sugar health market through the development of a series of innovative hypoglyc

      5/16/25 9:00:00 AM ET
      $BON
      Medicinal Chemicals and Botanical Products
      Health Care
    • Bon Natural Life Limited Announces Effectiveness of Reverse Stock Split

      XI'AN, China, May 15, 2025 (GLOBE NEWSWIRE) -- Bon Natural Life Limited (NASDAQ:BON) ("BON" or the "Company"), one of the leading bio-ingredient solutions providers in the natural, health and personal care industries, announced today that it will effect a 1-for-25 reverse stock split ("Reverse Stock Split") of its authorized, issued and outstanding Class A ordinary shares, par value $0.001 per share. The Reverse Stock Split will become effective at 12:01a.m., Eastern Time, on May 19, 2025. At such time, each 25 issued and outstanding Class A ordinary shares will automatically be reclassified into one new Class A ordinary share. Proportional adjustments will be made to outstanding equity aw

      5/15/25 6:15:00 AM ET
      $BON
      Medicinal Chemicals and Botanical Products
      Health Care